# A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors

> **NCT06172309** · PHASE1 · COMPLETED · sponsor: **Nanjing Chia-tai Tianqing Pharmaceutical** · enrollment: 32 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** NTQ1062

## Key facts

- **NCT ID:** NCT06172309
- **Lead sponsor:** Nanjing Chia-tai Tianqing Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-24
- **Primary completion:** 2024-04-20
- **Final completion:** 2024-05-27
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06172309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06172309, "A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06172309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*